• 首页
  • 关于期刊
    期刊简介
    编委会
    青年编委会
    合作单位
    《药学研究》编辑部
  • 投稿指南
  • 制度与声明
    出版伦理规范
    学术不端声明
    开放获取(OA)声明
    AIGC工具使用声明
  • 期刊订阅
  • 下载中心
  • English
引用本文:李秀峰,姚宗芹.养心生脉颗粒联合西药治疗冠心病心绞痛的临床疗效观察[J].药学研究,2022,41(4):271-272,276[点击复制]
【打印本页】      【下载PDF全文】   【查看/发表评论】  【下载PDF阅读器】  【关闭】
←前一篇|后一篇→ 过刊浏览    高级检索
本文已被:浏览 2531次   下载 2370次 本文二维码信息
码上扫一扫!
养心生脉颗粒联合西药治疗冠心病心绞痛的临床疗效观察
李秀峰,姚宗芹
字体:加大+|默认|缩小-
(临沂市中心医院,山东 临沂 276400)
摘要:
目的 观察养心生脉颗粒联合西药治疗冠心病心绞痛的临床效果。方法 选择2019年7月-2021年6月我院收治的冠心病心绞痛患者86例为研究对象,将患者随机分为观察组和对照组,每组各43例。对照组患者给予常规西药治疗,观察组则在对照组治疗的基础上加用养心生脉颗粒治疗。两组均连续治疗3周。观察两组的治疗效果、药物不良反应情况,比较两组患者治疗前后心绞痛发作的次数和持续时间。结果 治疗后观察组总有效率为95.35%,高于对照组的79.07%(P<0.05);治疗后,两组患者心绞痛发作次数和持续时间均较治疗前减少(P<0.05),且观察组患者的心绞痛发作次数和持续时间低于对照组(P<0.05)。两组不良反应发生率比较无显著差异。结论 养心生脉颗粒联合西药治疗冠心病心绞痛具有较好的疗效,可有效降低心绞痛发作次数和持续时间,安全性高,值得临床推广应用。
关键词:  养心生脉颗粒  冠心病  心绞痛  中西医结合疗法
DOI:10.13506/j.cnki.jpr.2022.04.014
基金项目:
出版日期:2022-04-25
Clinical observation of Yangxin Shengmai Granules combined with western medicine in the treatment of coronary heart disease and angina pectoris
LI Xiufeng,YAO Zongqin
(Linyi Central Hospital,Linyi 276400,China)
Abstract:
Objective To investigate the clinical efficacy of Yangxin Shengmai Granules combined with western medicine in the treatment of coronary heart disease and angina pectoris. Methods A total of 86 patients with angina pectoris of coronary heart disease admitted to our hospital from July 2019 to June 2021 were selected, patients were randomly divided into observation group and control group, 43 cases in each group. The control group was given routine western medicine treatment, and the observation group was given Yangxin Shengmai Granules treatment on the basis of the control group. Patients in two groups were treated for 3 weeks. After treatment, the clinical efficacy and incidence of adverse drug reactions were observed between the two groups, and the frequency and duration of angina pectoris in two groups before and after treatment were compared.Results After the treatment,the total effective rate of the observation group and the control group were 95.35% and 79.07%,respectively,the differences between the two groups were statistically significant (P<0.05).After the treatment,The frequency and duration of angina pectoris in two groups was significantly decreased(P<0.05), and were lower in the observation group than those in the control group(P<0.05). There was no significant difference in the incidence of adverse reactions between groups. Conclusion Yangxin Shengmai Granules combined with western medicine in the treatment of coronary heart disease and angina pectoris has good clinical efficacy,can effectively reduce the frequency and duration of angina pectoris,which is higher safe,and worthy of clinical application.
Key words:  Yangxin Shengmai Granules  Coronary heart disease  angina pectoris  Integrated traditional Chinese and western medicine therapy
今日访问量:2329    总访问量:55338697
网站版权:《药学研究》编辑部     鲁ICP备17018036号-3     鲁公网安备 37010202001351号
主办:山东省食品药品检验研究院、山东省药学会 地址:山东省济南市高新区新泺大街2749号 邮政编码:250101
电话:0531-81216586 电子邮箱:yaoxueyanjiu@163.com;yaoxueyanjiu@126.com
技术支持:北京勤云科技有限公司